Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

Background: Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients. Methods: Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacoki...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2012-08, Vol.107 (4), p.592-597
Hauptverfasser: Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H
Format: Artikel
Sprache:eng
Schlagworte:
631/92/436/108
692/699/67/589/466
692/700/565/1436/1437
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Benzamides
Benzenesulfonates - administration & dosage
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Bisphosphonates
Cancer Research
Cancer therapies
Castration
Chemotherapy
Clinical Study
Cytotoxicity
Drug Administration Schedule
Drug dosages
Drug Resistance
Epidemiology
Hematology
Humans
Imatinib Mesylate
Male
Maximum Tolerated Dose
Medical research
Medical sciences
Medicine
Metastasis
Middle Aged
Molecular Medicine
Nephrology. Urinary tract diseases
Niacinamide - analogs & derivatives
Oncology
Phenylurea Compounds
Piperazines - administration & dosage
Piperazines - pharmacokinetics
Prostate cancer
Prostatic Neoplasms - drug therapy
Pyridines - administration & dosage
Pyrimidines - administration & dosage
Pyrimidines - pharmacokinetics
Retreatment
Treatment Failure
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients. Methods: Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacokinetics (PK) were determined on day 15, 4 h post dose with a validated LC–MS assay. Results: Seventeen patients were enrolled; 10 evaluable (6 at 400 mg S qd with 300 mg IM qd (DL0) and 4 at 400 mg S bid with 300 mg IM qd (DL1)); inevaluable patients received
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2012.312